source
- Angelini fortifies neurology portfolio with $4.1B buyout of CatalystAngelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s po…Endpoints · 2mo ago↗ source
- Amgen, AbbVie say IRA negotiations impacted Q1 salesAt least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in thei…Endpoints · 2mo ago↗ source
- Lilly plans new $4.5B manufacturing investment in IndianaEli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest pharma company, headquarter…